# Article information:

Therapeutic peptides: Historical perspectives, current development trends, and future directions | Elsevier Enhanced Reader
[https://reader.elsevier.com/reader/sd/pii/S0968089617310222?token=2EC6F2C60C8112E46CF85287D9392C0102F02AC7871782C45425BB205D610A5349EE12140B25AC8BAC4FFCB06A602490=us-east-1=20230206101621](https://reader.elsevier.com/reader/sd/pii/S0968089617310222?token=2EC6F2C60C8112E46CF85287D9392C0102F02AC7871782C45425BB205D610A5349EE12140B25AC8BAC4FFCB06A602490&originRegion=us-east-1&originCreation=20230206101621)

# Article summary:

1. Peptides have historically been used as therapeutic agents, but the development of small molecules has shifted the focus away from peptides.

2. Small molecules are often less potent than peptides and more difficult to develop for certain types of receptors, but they can still be effective in some cases.

3. Recent advances in synthetic strategies and formulation technologies have made peptide drugs more viable, leading to a diverse and robust development landscape for therapeutic peptides.

# Article rating:

Appears moderately imbalanced: The article provides some useful information, but is missing several important points or pieces of evidence that would be required to present the discussed topics in a balanced and reliable way. You are encouraged to seek a more balanced perspective on the presented issues by exploring the provided research topics and looking at different information sources.

# Article analysis:

The article provides an overview of the history and current state of therapeutic peptides, with a focus on their advantages and disadvantages compared to small molecule drugs. The article is generally well-written and provides a comprehensive overview of the topic, though it does not explore any counterarguments or potential risks associated with using peptide drugs. Additionally, while the article mentions that there are over 60 approved peptide drugs in various countries, it does not provide any evidence or sources to support this claim. Furthermore, the article does not discuss any potential biases or conflicts of interest that may exist when discussing therapeutic peptides; for example, it does not mention whether any of the authors have financial ties to companies involved in developing these drugs. Finally, while the article mentions that there are over 150 active clinical trials involving peptide drugs, it does not provide any information about how successful these trials have been or what results they have yielded so far. In conclusion, while this article provides a good overview of therapeutic peptides and their current development trends, it could benefit from providing more evidence to support its claims as well as exploring potential biases and conflicts of interest related to this topic.

# Topics for further research:

* Therapeutic peptide drugs clinical trials
* Financial ties to peptide drug companies
* Advantages and disadvantages of peptide drugs
* Risks associated with peptide drugs
* Success rate of peptide drug clinical trials
* Conflicts of interest in peptide drug development

# Report location:

<https://www.fullpicture.app/item/658cb222727dd3f2768f0ac539f200c6>